Insulin glargine biosimilar in US delayed until end 2016

Biosimilars/News | Posted 23/10/2015 post-comment0 Post your comment

Pharmaceutical majors Eli Lilly and Sanofi announced on 28 September 2015 that the two companies had agreed to end the legal dispute over biosimilar insulin glargine in the US and to discontinue similar disputes worldwide.

Insulin 2 V13E10

The two companies have made a deal to resolve patent litigation brought by Sanofi against Eli Lilly and its partner, Boehringer Ingelheim (BI), regarding their insulin glargine product, Basaglar.

Under the terms of the agreement Eli Lilly and BI will be able to launch Basaglar in the US on 15 December 2016. As part of the agreement Eli Lilly will pay royalties to Sanofi to enable it to manufacture and sell Basaglar in the Kwikpen device globally.

This is quite a delay, considering the fact that the patents on the originator product, Lantus, expired in the US and Europe in 2014 [1]. Investors had also assumed that Eli Lilly would launch Basaglar at the latest in the US in June 2016, once the 30-month stay under the Hatch-Waxman Act triggered due to the patent litigation had expired.

Eli Lilly and BI’s biosimilar insulin glargine Basaglar was approved by the European Medicines Agency in September 2014 [2]. Eli Lilly has filed for a similar approval for its biosimilar insulin glargine product, Basaglar, in the US.

The settlement, according to Sanofi’s statement, does not cover the drug packaged in vials or any Lantus combination products.

Related articles
Biosimilar insulin launched in the UK

Biosimilars approved in Europe

References
1.   GaBI Online - Generics and Biosimilars Initiative. Biological patent expiries [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2015 Oct 23]. Available from: www.gabionline.net/Biosimilars/General/Biologicals-patent-expiries
2.   GaBI Online - Generics and Biosimilars Initiative. European approval for biosimilar insulin [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2015 Oct 23]. Available from: www.gabionline.net/Biosimilars/News/European-approval-for-biosimilar-insulin

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2015 Pro Pharma Communications International. All Rights Reserved.

Source: Eli Lilly, Reuters, Sanofi

comment icon Comments (0)
Post your comment
Related content
Etanercept biosimilars delayed until 2029 in US
Etanercept V14H14
Biosimilars/News Posted 14/01/2022
Canada approves filgrastim biosimilar Nypozi
Filgrastim Grastofil V13H23
Biosimilars/News Posted 14/01/2022
New Zealand announces funding for adalimumab biosimilar
02 AA010638
Biosimilars/News Posted 17/12/2021
China approves three bevacizumab copy biologicals
Bevacizumab 2 V14f01
Biosimilars/News Posted 10/12/2021
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010